Area of research
Pharmacology · Genetics
Research interest
Research focused on Efavirenz and CYP2B6, with related work in CYP2C19, Discontinuation, Escitalopram. Notable publications include 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing', 'PharmVar GeneFocus: CYP2B6', and 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy'.
Clinical Pharmacogenetics Implementation Consortium Guideline for <scp> <i>NAT2</i> </scp> Genotype and Hydralazine Therapy
PharmVar GeneFocus: <i>CYP2B6</i>
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C19</i> and Proton Pump Inhibitor Dosing
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2B6</i> and Efavirenz‐Containing Antiretroviral Therapy
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy
Citalopram and escitalopram plasma drug and metabolite concentrations: genome‐wide associations